Home›Research›Compare›Eloralintide vs Liraglutide
Peptide ComparisonEloralintide vs Liraglutide
Both are Metabolic peptides.
Eloralintide
LY3841136
Half-life: Not published
1 providers listed
Liraglutide
Victoza
Half-life: 13 hours
52 providers listed
Liraglutide is FDA-approved, while Eloralintide is investigational — the clearest structural difference between them.
Eloralintide
Half-life
Not published
Liraglutide
Half-life
13 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Liraglutide |
| Further along in FDA review | Liraglutide |
| More provider options (1 vs 52) | Liraglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Eloralintide
Liraglutide
Eloralintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…
Liraglutide
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
+4 more
About Eloralintide
Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Eloralintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.
Liraglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Where to source these peptides
Eloralintide
1 listed
Browse directory →
Providers offeringLiraglutide
52 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.